Carisma Therapeutics: Funding, Investors & Team (Oct 2026)
Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strong cellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease. Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania.
Carisma Therapeutics has raised $89.0M across 3 funding rounds on record, the most recent a Series C of $30.0M announced in Sep 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Carisma Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Carisma Therapeutics Funding Rounds
Carisma Therapeutics raised $47.0M in a Series B announced in Jan 2021.
2 months later, a Series B of $12.0M was announced in Mar 2021.
1.5 years later, a Series C of $30.0M was announced in Sep 2022.
Carisma Therapeutics Founders and Leadership Team
Contact details for the Carisma Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Carisma Therapeutics Funding Compared to Other Biotechnology Startups
Carisma Therapeutics' latest round of $30.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Carisma Therapeutics in Biotechnology and Philadelphia
Companies Similar to Carisma Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Carisma Therapeutics Funding FAQs
What does Carisma Therapeutics do?
Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strong cellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease. Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania.
How much funding has Carisma Therapeutics raised?
Carisma Therapeutics has raised $89.0M across 3 rounds on record. The most recent is a Series C of $30.0M announced in Sep 2022.
When did Carisma Therapeutics last raise funding?
Carisma Therapeutics' most recent funding round on record is a Series C of $30.0M, announced in Sep 2022.
Who founded Carisma Therapeutics?
FundedIQ lists Saar Gill (Founder) at Carisma Therapeutics.
Who is the CEO of Carisma Therapeutics?
Steven Kelly is listed as CEO at Carisma Therapeutics.
Where is Carisma Therapeutics headquartered?
Carisma Therapeutics is based in Philadelphia, Pennsylvania, United States.
How many employees does Carisma Therapeutics have?
Carisma Therapeutics is in the 51-100 employee band.
How does Carisma Therapeutics' funding compare to other Biotechnology startups?
Carisma Therapeutics' latest round of $30.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Carisma Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Carisma Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.